Skip to main content
Top
Published in: Head and Neck Pathology 1/2015

01-03-2015 | Proceedings of the North American Society of Head and Neck Pathology Companion Meeting, March 22, 2015, Boston, Massachusetts

When Thyroid Carcinoma Goes Bad: A Morphological and Molecular Analysis

Authors: Sylvia Papp, Sylvia L. Asa

Published in: Head and Neck Pathology | Issue 1/2015

Login to get access

Abstract

Thyroid carcinomas of follicular epithelial derivation are common and generally well-behaved malignancies with excellent cure and survival rates. However, a subset of these carcinomas, whether well-differentiated, poorly differentiated, or anaplastic, is highly aggressive, manifesting with local invasion, recurrence, and distant metastasis. The recognition of dedifferentiation is of paramount importance. In addition, the challenge for Pathologists is to identify the rare aggressive differentiated carcinomas so that treatment may be tailored appropriately. Thus, histological subtyping and documentation of other aggressive features such as widespread invasion and angioinvasion are critical. Mutational analyses in the past decade have delineated the molecular alterations responsible for thyroid carcinogenesis and progression, allowing greater sub-classification and prognostication of thyroid carcinomas. This review article highlights important aggressive morphologic features and molecular mutations associated with thyroid carcinoma.
Literature
1.
go back to reference Albores-Saavedra J, Henson DE, Glazer E, et al. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype–papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18:1–7.CrossRefPubMed Albores-Saavedra J, Henson DE, Glazer E, et al. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype–papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18:1–7.CrossRefPubMed
2.
go back to reference O’Neill CJ, Oucharek J, Learoyd D, et al. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist. 2010;15:146–56.CrossRefPubMedCentralPubMed O’Neill CJ, Oucharek J, Learoyd D, et al. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist. 2010;15:146–56.CrossRefPubMedCentralPubMed
3.
go back to reference Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol. 2011;24:1545–52.CrossRefPubMed Mete O, Asa SL. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol. 2011;24:1545–52.CrossRefPubMed
4.
go back to reference Brierley JD, Asa SL. Thyroid cancer. Chapter 11. In: Gospodarowicz MK, O’Sullivan B, Sobin L (Eds): Prognostic factors in cancer. Third edition, Wiley-Liss Inc. 2006;119–122. Brierley JD, Asa SL. Thyroid cancer. Chapter 11. In: Gospodarowicz MK, O’Sullivan B, Sobin L (Eds): Prognostic factors in cancer. Third edition, Wiley-Liss Inc. 2006;119–122.
5.
go back to reference The Cancer Genome Atlas ResearchNetwork. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–90.CrossRef The Cancer Genome Atlas ResearchNetwork. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–90.CrossRef
6.
go back to reference D’Avanzo A, Treseler P, Ituarte PHG, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer. 2004;100:1123–9.CrossRefPubMed D’Avanzo A, Treseler P, Ituarte PHG, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer. 2004;100:1123–9.CrossRefPubMed
7.
go back to reference Cheng S, Serra S, Mercado M, et al. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res. 2011;17:2385–94.CrossRefPubMed Cheng S, Serra S, Mercado M, et al. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res. 2011;17:2385–94.CrossRefPubMed
8.
go back to reference Asioli S, Erickson LA, Sebo TJ, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010;34:44–52.CrossRefPubMed Asioli S, Erickson LA, Sebo TJ, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010;34:44–52.CrossRefPubMed
9.
go back to reference Ghossein R. Encapsulated malignant follicular cell-derived thyroid tumors. Endocr Pathol. 2010;21:212–8.CrossRefPubMed Ghossein R. Encapsulated malignant follicular cell-derived thyroid tumors. Endocr Pathol. 2010;21:212–8.CrossRefPubMed
10.
go back to reference Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of RAS mutations. Am J Clin Pathol. 2003;120:71–7.CrossRefPubMed Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of RAS mutations. Am J Clin Pathol. 2003;120:71–7.CrossRefPubMed
11.
go back to reference Rivera M, Ricarte-Filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histologic subtypes (encapsulated vs non-encapsulated infiltrative) reveals distinct BRAF and RAS mutations. Mod Pathol. 2010;23:1191–200.CrossRefPubMed Rivera M, Ricarte-Filho J, Knauf J, et al. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histologic subtypes (encapsulated vs non-encapsulated infiltrative) reveals distinct BRAF and RAS mutations. Mod Pathol. 2010;23:1191–200.CrossRefPubMed
12.
go back to reference Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31:1256–64.CrossRefPubMed Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31:1256–64.CrossRefPubMed
13.
go back to reference Hannallah J, Rose J, Guerrero MA. Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma. Int J Endocrinol. 2013;Article ID 317487. Hannallah J, Rose J, Guerrero MA. Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma. Int J Endocrinol. 2013;Article ID 317487.
14.
go back to reference Asioli S, Erickson LA, Righi A, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol. 2010;23:1269–78.CrossRefPubMed Asioli S, Erickson LA, Righi A, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol. 2010;23:1269–78.CrossRefPubMed
15.
go back to reference Garcia-Rostan G, Sobrinho-Simões M. Poorly differentiated thyroid carcinoma: an evolving entity. Diagn Histopathol. 2011;17:114–23.CrossRef Garcia-Rostan G, Sobrinho-Simões M. Poorly differentiated thyroid carcinoma: an evolving entity. Diagn Histopathol. 2011;17:114–23.CrossRef
16.
go back to reference Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev. 2006;6:292–306.CrossRef Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev. 2006;6:292–306.CrossRef
17.
go back to reference Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA. 2009;106:4519–24.CrossRefPubMedCentralPubMed Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA. 2009;106:4519–24.CrossRefPubMedCentralPubMed
18.
go back to reference Namba H, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393–7.CrossRefPubMed Namba H, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88:4393–7.CrossRefPubMed
19.
go back to reference Nikiforova MN, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–404.CrossRefPubMed Nikiforova MN, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–404.CrossRefPubMed
20.
go back to reference Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57:1690–4.PubMed Nikiforov YE, Rowland JM, Bove KE, et al. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57:1690–4.PubMed
21.
go back to reference Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer. 2002;2:543–9.CrossRefPubMed Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer. 2002;2:543–9.CrossRefPubMed
22.
go back to reference Park JY, Kim WY, Hwang TS, et al. BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma. Endocr Pathol. 2013;24:69–76.CrossRefPubMed Park JY, Kim WY, Hwang TS, et al. BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma. Endocr Pathol. 2013;24:69–76.CrossRefPubMed
23.
go back to reference Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130:736–44.CrossRefPubMed Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008;130:736–44.CrossRefPubMed
24.
go back to reference Asa SL, Giordano TJ, LiVolsi VA. Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist? Thyroid. 2014;Online, ahead of print. PMID:25409450. Asa SL, Giordano TJ, LiVolsi VA. Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist? Thyroid. 2014;Online, ahead of print. PMID:25409450.
25.
go back to reference Volante M, Rapa I, Gandhi M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94:4735–41.CrossRefPubMed Volante M, Rapa I, Gandhi M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94:4735–41.CrossRefPubMed
26.
go back to reference Eberhardt NL, Grebe SK, McIver B, et al. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol. 2010;321:50–6.CrossRefPubMedCentralPubMed Eberhardt NL, Grebe SK, McIver B, et al. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol. 2010;321:50–6.CrossRefPubMedCentralPubMed
28.
29.
go back to reference Elliott DD, Sherman SI, Bisaidy NL, et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008;39:15–20.CrossRefPubMed Elliott DD, Sherman SI, Bisaidy NL, et al. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. Hum Pathol. 2008;39:15–20.CrossRefPubMed
30.
go back to reference Kondo T, Zheng L, Liu W, et al. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res. 2007;67:5461–70.CrossRefPubMed Kondo T, Zheng L, Liu W, et al. Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res. 2007;67:5461–70.CrossRefPubMed
31.
go back to reference Logan A, Black EG, Gonzalez AM, et al. Basic fibroblast growth factor: an autocrine mitogen of rat thyroid follicular cells? Endocrinology. 1992;130:2363–72.CrossRefPubMed Logan A, Black EG, Gonzalez AM, et al. Basic fibroblast growth factor: an autocrine mitogen of rat thyroid follicular cells? Endocrinology. 1992;130:2363–72.CrossRefPubMed
32.
go back to reference St. Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 2005;146:1145–53.CrossRefPubMed St. Bernard R, Zheng L, Liu W, et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 2005;146:1145–53.CrossRefPubMed
33.
go back to reference Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 2006;91:3667–70.CrossRefPubMed Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 2006;91:3667–70.CrossRefPubMed
34.
go back to reference Khoo ML, Beasley NJ, Ezzat S, et al. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2002;87:1814–8.CrossRefPubMed Khoo ML, Beasley NJ, Ezzat S, et al. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2002;87:1814–8.CrossRefPubMed
35.
go back to reference Khoo ML, Ezzat S, Freeman JL, et al. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab. 2002;87:1810–3.CrossRefPubMed Khoo ML, Ezzat S, Freeman JL, et al. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab. 2002;87:1810–3.CrossRefPubMed
Metadata
Title
When Thyroid Carcinoma Goes Bad: A Morphological and Molecular Analysis
Authors
Sylvia Papp
Sylvia L. Asa
Publication date
01-03-2015
Publisher
Springer US
Published in
Head and Neck Pathology / Issue 1/2015
Electronic ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-015-0619-z

Other articles of this Issue 1/2015

Head and Neck Pathology 1/2015 Go to the issue

Proceedings of the North American Society of Head and Neck Pathology Companion Meeting, March 22, 2015, Boston, Massachusetts

Mutant Allele Tumor Heterogeneity (MATH) and Head and Neck Squamous Cell Carcinoma